American Psychiatric Association (1990) Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report. American Psychiatric Association.
Bauer, M. S. (2002) A review of quantitative studies of adherence to mental health clinical practice guideline. Harvard Review of Psychiatry, 10, 138–153.
Caswell, L., Hoosen, I., Vassilas, C. A., et al (2006) Reducing hypnotic use in two older adult functional wards: an effective audit?
Psychiatric Bulletin, 30, 95–97.
Department of Health and Children (2002) Report of the Benzodiazepine Committee. Republic of Ireland Government Publications.
Dollman, W. B., Leblanc, V.T., Stevens, L., et al (2005) Achieving a sustained reduction in benzodiazepine use through implementation of an are awide multistrategic approach. Journal of Clinical Pharmacy and Therapeutics, 30, 425–432.
Hamann, J., Ruppert, A., Auby, P., et al (2003) Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. International Clinical Psychopharmacology, 18, 237–242.
Hannon, N., Hamzah, Z., Akinpeloye, H., et al (2007) Venlafaxine–mirtazapine combination in the treatment of persistent depressive illness. Journal of Psychopharmacology, 21, 161–165.
Harrington, M., Lelliott, P., Paton, C., et al (2002) The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bulletin, 26, 414–418.
Hodgson, R. & Belgamwar, R. (2006) Off-label prescribing by psychiatrists. Psychiatric Bulletin, 30, 55–57.
Karow, A. & Lambert, M. (2003) Polypharmacy in treatment with psychotropic drugs: the underestimated phenomenon. Current Opinion in Psychiatry, 16, 713–718.
Lieberman, J. A. (2004) Metabolic changes associated with antipsychotic use. Journal of Clinical Psychiatry, 6 (suppl 2), 8–13.
Mahomed, R., Paton, C. & Lee, E. (2002) Prescribing hypnotics in a mental health trust: what consultant psychiatrists say and what they do. Pharmaceutical Journal, 268, 657–659.
Meagher, D. & Moran, M. (2003) Sub-optimal prescribing in an adult community mental health service: prevalence and determinants. Psychiatric Bulletin, 27, 266–270.
Meagher, D., Hannan, N. & Leonard, M. (2006) Duloxetine–mirtazapine combination in depressive illness: the case for Limerick ‘rocket fuel’. Irish Journal of Psychological Medicine, 23, 116–118.
Moran, M., Raju, B. & Saunders, J., et al (2006). Achieving evidence-based prescribing practice in an adult community mental health service. Psychiatric Bulletin, 30, 51–55.
Mortimer, A. M., Shepherd, C. J., Rymer, M., et al (2005) Primary care use of antipsychotic drugs: an audit and intervention study. Annals of General Psychiatry, 4, 18.
Parks, J. & Surles, R. (2004) Using best practices to manage psychiatric medications under Medicaid. Psychiatric Services, 55, 1227–1229.
Raju, B. & Meagher, D. (2005) Patient-controlled benzodiazepine dose reduction in a community mental health service. Irish Journal of Psychological Medicine, 22, 42–45.
Reilly, J. G., Avis, S. A., Ferrier, I. N., et al (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet, 355, 1048–1052.
Royal College of Psychiatrists (2007) Use of Licensed Medicines for Unlicensed Applications in Psychiatric Practice
. Royal College of Psychiatrists.
Schneider, L. S., Dagerman, K. S. & Insel, P. (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 294, 1934–1943.
Simpson, S., Beavis, D., Leddy, A., et al (2005) Naturalistic audit of NICE criteria for the use of cholinesterase inhibitors. Psychiatric Bulletin, 29, 410–412.
Soumerai, S. B. (2004) Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Affairs, 23, 135–146.
Spinewine, A., Swine, C., Dhillon, S., et al (2007) Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomised controlled trial. Journal of the American Geriatrics Society, 55, 658–665.
Stone, J., Ohlsen, R., Taylor, D., et al (2002) Naturalistic study of the antipsychotic medication review service at the Maudsley Hospital. Psychiatric Bulletin, 26, 291–294.
Tamblyn, R., Laprise, R., Hanley, J. A., et al (2001) Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA, 285, 421–429.
Voshaar, R. C., Gorgels, W. J., Mol, A. J., et al (2003) Tapering off long-term benzodiazepine use with or without group cognitive–behavioural therapy: three-condition, randomised controlled trial. British Journal of Psychiatry, 182, 498–504.
Wagner, A. K., Ross-Degnan, D., Gurwitz, J. H., et al (2007) Effect of New York state regulatory action on benzodiazepine prescribing and hip fracture rates. Annals of Internal Medicine, 146, 96–103.
Williams, D. D. R. & McBride, A. (1999) Benzodiazepines: time for reassessment. British Journal of Psychiatry, 173, 361–362.
World Health Organization (1990) Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. British Journal of Psychiatry, 156, 412.